Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer

Next Previous
Trial Profile

A Randomized, Double-blind, Phase III Study of BD0801 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in Patients With Recurrent, Platinum-resistant Epithelial Ovarian, Fallopian Tube , or Primary Peritoneal Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Suvemcitug (Primary) ; Doxorubicin liposomal; Paclitaxel; Topotecan
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORES
  • Sponsors Jiangsu Simcere Pharmaceutical

Most Recent Events

  • 07 Dec 2026 According to a Simcere Pharmaceutical Group Ltd media release, based on data from this study the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Ovarian Cancer has listed Suvemcitug as a preferred regimen for the treatment of platinum-resistant recurrent ovarian cancer
  • 09 Jan 2026 Results published in Nature Cancer.
  • 11 Sep 2025 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top